India, June 3 -- Quoin Pharmaceuticals, Ltd. (QNRX), a late clinical-stage pharmaceutical company, announced that it has submitted the Investigational New Drug application, or IND, for QRX003 to the U.S. Food and Drug Administration, or FDA, for the treatment of Peeling Skin Syndrome, or PSS.
The IND submission is based on the encouraging results observed from Quoin's ongoing investigator-led pediatric PSS study. The firm expects to initiate a Phase 2 clinical study for QRX003 in the second half of 2026 after the review results.
Generalised inflammatory PSS is a rare autosomal recessive genodermatosis that is caused by variants of the corneodesmosin gene, or CDSN, which results in excessive shedding of the epidermis. It is characterised b...